Drug: Xeljanz (tofacitinib)

Manufacturer: Pfizer

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication:

• • treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adult patients with moderately-to-severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of active polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers

Disease: atopic dermatitis, ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

Enrollment Form Link: XELSOURCE

Phone Number: 1-844-935-5269

Fax Number: 1-866-297-3471

Product Website: xeljanz.com